EUCTR2008-008392-34-IT进行中（未招募）不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation with an Intramedullary Nail - AMG 785 20062017
Amgen Inc.0 个研究点目标入组 400 人开始时间: 2009年11月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Skeletally mature adults, age ≥18 to ≤ 85 years at randomization, with radiographically closed growth plates Fresh unilateral closed or Gustilo type I or type II open tibial fracture as the primary injury For closed fractures: Definitive fracture fixation with reamed IM nailing (modern, statically, interlocking nail) performed no later than 14 days after injury For Gustilo type I/II open fractures: Definitive fracture fixation with reamed or unreamed IM nailing (modern, statically, interlocking nail) performed no later than 24 hours after injury
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Major polytrauma or significant axial trauma, with injury severity score >16Head-injury, as defined by Glasgow Coma Scale <13 at time of randomization Associated fracture of the lower extremity that, in the opinion of the surgeon, will delay the subjects ability to bear weight beyond the normal time expected for a tibial shaft fractureUse of bone grafts at the time of definitive fracture fixationHistory of pathological fracture or metabolic or bone disease that may interfere with the interpretation of the results, such as Pagets disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushings disease, hyperprolactinemia History of spinal stenosisHistory of facial nerve paralysisMalignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical carcinoma in situ) within the last 5 yearsHistory of solid organ or bone marrow transplantsEvidence of the following per subject report, chart review or local laboratory result (currently or within the past 5 years)oElevated transaminases (≥ 2.0 x upper limits of normal)oSignificantly impaired renal function as determined by a derived creatinine clearance of ≤ 30 mL/min using the Modification of Diet in Renal Disease equation-Current hypercalcemia or hypocalcaemia (outside of the normal range)-hypoalbuminemia (below lower limit of normal)Known to have tested positive for human immunodeficiency virus, hepatitis C virus, or hepatitis B surface antigenUse of the following agents affecting bone metabolism: intravenous bisphosphonates at any time; denosumab at any time; fluoride (for osteoporosis) within the past 24 months; oral bisphosphonates, parathyroid hormone or strontium within the past 12 months; calcitonin, selective estrogen receptor Modulators, systemic oral or transdermal estrogen within the past three months (estrogen-containing contraceptive therapy is permitted); systemic glucocorticosteroids(≥5 mg prednisone equivalent per day for more than 10 days) within the past three months, or tibolone within the past three months; BMP-2 or BMP-7 at the time of definitive fracture fixation Current use of anticoagulants (doses for deep vein thrombosis prophylaxis are permitted)Currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or subject is receiving other investigational agentsPrevious enrollment in an AMG 785 clinical study Subject of child-bearing potential who is evidently pregnant(eg, positive human chorionic gonadotropin test) or breast-feedingFemales of childbearing potential: Subject refuses to use 2 different forms of effective contraception in order to achieve a highly effective contraception result during treatment with study drug and for an additional 5 months after the end of treatment with study drug Sexually active males with a female partner of childbearing potential: Subject in combination with his partner refuses to use 2 different forms of effective contraception in order to achieve a highly effective contraception result during treatment with study drug and for an additional 7 months after the end of treatment with study drugMales with a partner who is pregnant: Subject refuses to use a condom during treatment with study drug and for an additional 7 months after the end of treatment with study drugKnown intolerance to calcium supplements or vitamin D productsKnown sensitivity to mammalian cell derived d
研究者
相似试验
进行中（未招募）
1 期
A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation with an Intramedullary Nail - Study To Assess Healing of Repaired Tibias with SclerosTin Antibody (STARTT) - Study To Assess Healing of Repaired Tibias with SclerosTin Antibody (STARTT)Acceleration of fracture healingMedDRA version: 13.1 Level: PT Classification code 10043827 Term: Tibia fracture System Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2008-008392-34-GBAmgen Inc400
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors.Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa, con o sin quimioterapia adyuvante, en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo. - RADIANTEUCTR2005-001747-29-ESOSI Pharmaceuticals, Inc.945
进行中（未招募）
不适用
Study of AMG785 in hip fractureAcceleration of fracture healingMedDRA version: 14.1Level: PTClassification code 10016454Term: Femur fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2009-015939-33-BEAmgen Inc330
进行中（未招募）
1 期
/aEUCTR2015-005241-31-NOEryDel S.p.A.175
进行中（未招募）
不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine theEfficacy, Safety, and Tolerability of AMG 785 in Adults with Fresh Unilateral Intertrochanteric Fracture of the Proximal Femur, Status Post Fixation with a Sliding Hip Screw or Intramedullary NailEUCTR2009-015939-33-SEAmgen Inc330